Prosecution Insights
Last updated: November 04, 2026
Application No. 17/911,302

COMPOSITIONS, METHODS AND USES OF COMBINATION TREATMENTS FOR BLOOD CANCERS

Non-Final OA §103§112§DP
Filed
Sep 13, 2022
Priority
Mar 13, 2020 — provisional 62/989,440 +1 more
Examiner
CHICKS, ASHLI ARIANA
Art Unit
1626
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
University Of New Brunswick
OA Round
3 (Non-Final)
59%
Grant Probability
Moderate
3-4
OA Rounds
0m
Est. Remaining
99%
With Interview

Examiner Intelligence

Grants 59% of resolved cases
59%
Career Allowance Rate
57 granted / 96 resolved
-0.6% vs TC avg
Strong +52% interview lift
Without
With
+51.7%
Interview Lift
resolved cases with interview
Typical timeline
3y 4m
Avg Prosecution
47 currently pending
Career history
141
Total Applications
across all art units

Statute-Specific Performance

§101
1.5%
-38.5% vs TC avg
§103
28.7%
-11.3% vs TC avg
§102
21.6%
-18.4% vs TC avg
§112
25.1%
-14.9% vs TC avg
Black line = Tech Center average estimate • Based on career data from 96 resolved cases

Office Action

§103 §112 §DP
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim Status Claims 1, 3-4, 6, 8-9, 13-14, 20-21, 24, 28, 34-36, 73-77, 79-81, 90, 93, 97 and 103-105 are pending. Claims 8, 14, 20-21, 24, 28, 34-36, 73-77, 79-81, 90, 93, 97 and 103-105 are withdrawn. Claims 1, 3-4, 6, 9 and 13 are rejected. Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on September 21st, 2026, has been entered. Response to Amendment Applicant’s amendments have overcome the previously presented rejections. Election/Restrictions As per MPEP 803.02, the examiner will determine whether the entire scope of the claims is patentable. Applicant’s elected species combination of Panobinostat as a downregulating agent and As26 as the CAPE-related compound is not allowable. Therefore, examination has been limited to claims embracing the elected species which are claims 1, 3-4, 6, 9 and 13. Claims 1, 3-4, 6, 9 and 13 have been examined to the extent that they are readable on the elected embodiment. Subject matter not embraced by the elected embodiment is therefore withdrawn from further consideration. Claims 8, 14, 20-21, 24, 28, 34-36, 73-77, 79-81, 90, 93, 97 and 103–105 are withdrawn from further consideration by the examiner, 37 CFR 1.142(b), as being drawn to a non-elected invention. Claim Rejections - 35 USC § 112(a) The following is a quotation of the first paragraph of 35 U.S.C. 112(a): (a) IN GENERAL.—The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor or joint inventor of carrying out the invention. The following is a quotation of the first paragraph of pre-AIA 35 U.S.C. 112: The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same, and shall set forth the best mode contemplated by the inventor of carrying out his invention. Claims 1, 3-4, 6, 9 and 13 are rejected under 35 U.S.C. 112(a) or 35 U.S.C. 112 (pre-AIA ), first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor or a joint inventor, or for applications subject to pre-AIA 35 U.S.C. 112, the inventor(s), at the time the application was filed, had possession of the claimed invention. Claim 1 has been amended to exclude Hodgkin’s blood cancers as follows: PNG media_image1.png 378 722 media_image1.png Greyscale On page 10 of the remarks filed September 21st, 2026, Applicant states that claim 1 has been amended to exclude Hodgkin lymphoma from the class of blood cancers but is silent as to where support is provided in the specification for this amendment. The specification refers to the blood cancers generically using the language of claim 5 which recites the following blood cancers: myeloma, leukemia, and lymphoma (Ex: page 2, paragraph 2). There is no mention of Hodkin’s disease or Hodkin’s blood cancers. This type of situation is discussed in MPEP 2173.05(i): Any negative limitation or exclusionary proviso must have basis in the original disclosure. If alternative elements are positively recited in the specification, they may be explicitly excluded in the claims. See In re Johnson, 558 F.2d 1008, 1019, 194 USPQ 187, 196 (CCPA 1977) ("[the] specification, having described the whole, necessarily described the part remaining."). See also Ex parte Grasselli, 231 USPQ 393 (Bd. App. 1983), aff’d mem., 738 F.2d 453 (Fed. Cir. 1984). In describing alternative features, the applicant need not articulate advantages or disadvantages of each feature in order to later exclude the alternative features. See Inphi Corporation v. Netlist, Inc., 805 F.3d 1350, 1356-57, 116 USPQ2d 2006, 2010-11 (Fed. Cir. 2015). The mere absence of a positive recitation is not basis for an exclusion. However, a lack of literal basis in the specification for a negative limitation may not be sufficient to establish a prima facie case for lack of descriptive support. Ex parte Parks, 30 USPQ2d 1234, 1236 (Bd. Pat. App. & Inter. 1993). "Rather, as with positive limitations, the disclosure must only 'reasonably convey[] to those skilled in the art that the inventor had possession of the claimed subject matter as of the filing date.' ... While silence will not generally suffice to support a negative claim limitation, there may be circumstances in which it can be established that a skilled artisan would understand a negative limitation to necessarily be present in a disclosure." Novartis Pharms. Corp. v. Accord Healthcare, Inc., 38 F.4th 1013, 2022 USPQ2d 569 (Fed. Cir. 2022) (quoting Ariad Pharm. Inc. v. Eli Lilly & Co., 589 F.3d 1336, 1351, 94 USPQ2d 1161, 1172). Any claim containing a negative limitation which does not have basis in the original disclosure should be rejected under 35 U.S.C. 112(a) or pre-AIA 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. In this situation, the specification does not provide support for the instantly excluded type of blood cancer. Applicant is further directed to In re Bimeda Research & Dev. Ltd., 107 USPQ2d 1619 (Fed. Cir. 2013), which addressed exclusion of an unnamed species from a broader generic scope. Similarly, the court in Santarus Inc. v. Par Pharmaceutical Inc., 104 USPQ2d 1641 (Fed. Cir. 2012) addressed support for negative limitations as follows on page 1647: Negative claim limitations are adequately supported when the specification describes a reason to exclude the relevant limitation. Such written description support need not rise to the level of disclaimer. In fact, it is possible for the patentee to support both in the inclusion and exclusion of the same material. The claim limitation that the Phillips formulations contain no sucralfate is adequately supported by statements in the specification expressly listing the disadvantages of using sucralfate. […] The instant specification fails to disclose either a positive recitation of the presently excluded species or a disclaimer thereof. For these reasons, instant claims 1, 3-4, 6, 9 and 13 that are affected by the provision are rejected as containing new matter. Claim Rejections - 35 USC § 112(b) The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 3-4, 6 and 13 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. Claim 3 refers to the method of claim 2 which has been cancelled therefore it is unclear exactly what is embraced by the claimed method. Likewise, claim 6 recites the method of claim 5 which has been canceled. Claims 4 and 13 are rejected as they depend from claim 3, which is indefinite. Claim Interpretation Claims 3 and 6 have been treated as depending from claim 1 in the 35 USC 103 and nonstatutory double patenting rejections set forth below. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. Claim(s) 1, 3-4, 6, 9 and 13 are rejected under 35 U.S.C. 103 as being unpatentable over WO 2017/147718 A1 by Touaibia et al. in view of Bernard, et al. (2008). Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise. Current pharmaceutical design, 14(21), 2051–2060. and Bailey et al. “Panobinostat for the treatment of multiple myeloma: the evidence to date.” Journal of blood medicine vol. 6 269-76. 8 Oct. 2015. Determining the scope and contents of the prior art. (See MPEP § 2141.01) The prior art discloses (title) “modulators of lipoxygenase and cyclooxygenase enzyme activity” including compound 152 which is identical to As26 of instant claim 9 (page 33, Table 9). Compound 152 is represented by the structure below: PNG media_image2.png 292 540 media_image2.png Greyscale . Regarding instant claims 1 and 9, Touaibia et al. teach a method of treating a lipoxygenase and/or a cyclooxygenase-mediated disease by administering the prior art compound (paragraphs [0019]-[0020]). Ascertainment of the differences between the prior art and the claims. (See MPEP § 2141.02) Touaibia et al. disclose a method of treating lipoxygenase and/or cyclooxygenase-mediated diseases including some cancers by administering the prior art compound but do not teach that the compound is useful for treating non-Hodgkin blood cancers. Furthermore, the prior art is silent to the use of a downregulating agent and the downregulation effect of CAPE analog wherein the compound reduces the number of cancer cells, tumor burden or tumor growth in the patient. Finding of prima facie obviousness --- rationale and motivation (See MPEP § 2142-2143) Bernard et al. discuss (title) “Targeting cyclooxygenase-2 in hematological malignancies: rationale and promise” and teach (abstract): Malignancies of hematopoietic and non-hematopoietic origin often have increased expression of cyclooxygenase-2 (Cox-2), a key modulator of inflammation. For example, hematological malignancies such as chronic lymphocytic leukemia, chronic myeloid leukemia, Hodgkin’s lymphoma, non-Hodgkin’s lymphoma and multiple myeloma often highly express Cox-2, which correlates with poor patient prognosis. Expression of Cox-2 enhances survival and proliferation of malignant cells, while negatively influencing anti-tumor immunity. Hematological malignancies expressing elevated levels of Cox-2 potentially avoid immune responses by producing factors that enhance angiogenesis and metastases. Cellular immune responses regulated by natural killer cells, cytotoxic T lymphocytes, and T regulatory cells are also influenced by Cox-2 expression. Therefore, Cox-2 selective inhibitors have promising therapeutic potential in patients suffering from certain hematological malignancies. Accordingly, a person of ordinary skill seeking to treat additional cyclooxygenase mediated diseases in the method of Touaibia et al. would have been motivated to administer cyclooxygenase inhibitor compound 152 to improve therapeutic outcomes in subjects with blood cancers such as certain leukemias non-Hodgkin’s lymphomas or multiple myeloma. Regarding instant claims 1, 3-4, and 13, the patent’s claims are silent to contacting the blood cancer cells with a downregulating agent such as an HDAC inhibitor however MPEP 2144.06 suggests: "It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose.... [T]he idea of combining them flows logically from their having been individually taught in the prior art." In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980) Bailey et al. teach the following regarding Panobinostat for treating blood cancers (page 70): Panobinostat (LBH589) is a pan-deacetylase inhibitor belonging to hydroxamic acid family of compounds and is active against class I, II, and IV HDAC enzymes.19 Panobinostat has potent cytotoxic activity against tumor cells, while displaying minimal toxicity against normal cells.19 It inhibits the removal of acetyl groups by HDAC enzymes, leading to maintenance of acetylation of histone and nonhistone proteins. As a result, accumulation of histones and other proteins occurs, causing cell cycle arrest and apoptosis of cancer cells of various cancer types. Panobinostat has demonstrated potent preclinical activity in several hematologic malignancies such as acute myeloid leukemia, cutaneous T-cell lymphoma, chronic myeloid leukemia, and multiple myeloma… Accordingly, a person of ordinary skill seeking to treat blood cancers including leukemia or multiple myeloma in the method of Touaibia et al. and Bernard et al. would have been motivated to administer Compound 152 in combination with the HDAC inhibitor panobinostat in order to improve therapeutic outcomes. Although the prior art does not explicitly recite the intended use and effects of the instant claims a compound and its properties are inseparable so the properties of the instant compound would be inherent in the prior art given that the compounds are identical. Thus, the instant method of treating a non-Hodgkin’s blood cancer by administering a CAPE analog and downregulating agent to downregulate a cancer gene or protein target expression is obvious in view of the method of Touaibia et al., Bernard et al. and Bailey et al. which involves administering the instant combination to treat said cancer. A person of ordinary skill performing the combined could expect to achieve the same reduction in cancer cells, tumor burden, etc. recited by administering compound 152 and Panobinostat as taught in the prior art. Double Patenting The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 1, 3-4, 6, 9 and 13 are rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1-22 of U.S. Patent No. 12,605,352 in view Bailey et al. “Panobinostat for the treatment of multiple myeloma: the evidence to date.” Journal of blood medicine vol. 6 269-76. 8 Oct. 2015. Claim 1 of the patent discloses a method of inhibiting the growth of blood cancer cells by contacting the cells with As26 which identical to As26 of instant claim 9 (Col. 20); this method embraces the instant method of treating blood cancers by administering CAPE analog As26. Claims 2, 5, and 9 of the patent further teach that the blood cancer cells are multiple myeloma cells, lymphoma cells, or leukemia cells which corresponds to instant claims 1 and 6 (Col. 20). Regarding instant claims 1, 3-4, and 13, the patent’s claims are silent to contacting the blood cancer cells with a downregulating agent such as an HDAC inhibitor however MPEP 2144.06 suggests: "It is prima facie obvious to combine two compositions each of which is taught by the prior art to be useful for the same purpose, in order to form a third composition to be used for the very same purpose.... [T]he idea of combining them flows logically from their having been individually taught in the prior art." In re Kerkhoven, 626 F.2d 846, 850, 205 USPQ 1069, 1072 (CCPA 1980) Bailey et al. teach the following regarding Panobinostat for treating blood cancers (page 270): Panobinostat (LBH589) is a pan-deacetylase inhibitor belonging to hydroxamic acid family of compounds and is active against class I, II, and IV HDAC enzymes.19 Panobinostat has potent cytotoxic activity against tumor cells, while displaying minimal toxicity against normal cells.19 It inhibits the removal of acetyl groups by HDAC enzymes, leading to maintenance of acetylation of histone and nonhistone proteins. As a result, accumulation of histones and other proteins occurs, causing cell cycle arrest and apoptosis of cancer cells of various cancer types. Panobinostat has demonstrated potent preclinical activity in several hematologic malignancies such as acute myeloid leukemia, cutaneous T-cell lymphoma, chronic myeloid leukemia, and multiple myeloma… Accordingly, a person of ordinary skill seeking to inhibit the growth of multiple myeloma or leukemia cells in the patent’s method would have been motivated to administer As26 in combination with the HDAC inhibitor panobinostat in order to improve therapeutic outcomes. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to ASHLI A CHICKS whose telephone number is (571)270-0582. The examiner can normally be reached M-Th 7 a.m.- 5 p.m.. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, James H Alstrum-Acevedo can be reached at (571)272-5548. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /A.A.C./Examiner, Art Unit 1626 /KAMAL A SAEED/Primary Examiner, Art Unit 1626
Read full office action

Prosecution Timeline

Sep 13, 2022
Application Filed
Sep 08, 2025
Response after Non-Final Action
Nov 04, 2025
Non-Final Rejection mailed — §103, §112, §DP
May 04, 2026
Response Filed
May 19, 2026
Final Rejection mailed — §103, §112, §DP
Sep 21, 2026
Request for Continued Examination
Sep 22, 2026
Response after Non-Final Action
Oct 02, 2026
Non-Final Rejection mailed — §103, §112, §DP (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12781051
COMPOSITION, DICHROIC SUBSTANCE, LIGHT ABSORPTION ANISOTROPIC FILM, LAMINATE, AND IMAGE DISPLAY DEVICE
7y 2m to grant Granted Nov 03, 2026
Patent 12773464
SELECTIVE LIGANDS FOR TAU AGGREGATES
4y 6m to grant Granted Oct 27, 2026
Patent 12735432
PARP INHIBITOR CONTAINING PIPERAZINE STRUCTURE, PREPARATION METHOD THEREFOR AND PHARMACEUTICAL USE THEREOF
3y 0m to grant Granted Sep 15, 2026
Patent 12715877
PROTEIN DEGRADERS AND USES THEREOF
4y 2m to grant Granted Aug 25, 2026
Patent 12679842
HCK AS A THERAPEUTIC TARGET IN MYD88 MUTATED DISEASES
4y 3m to grant Granted Jul 14, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
59%
Grant Probability
99%
With Interview (+51.7%)
3y 4m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 96 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month